Evogene Ltd (EVGN) Fair Value & Analysis
Healthcare · US · Market cap $6.4M
Evogene Ltd
EVGN · US
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 10 days ago
Share price −27.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.4529 – $1.73 · fair‑value band $0.8400 – $1.39 · the $0.4990 price screens below the $1.11 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Evogene Ltd (EVGN) currently trades at $0.4990, while our model-based Fair Value estimate is $1.11 — implying the stock looks roughly 122.4% undervalued today. We read business quality at 26/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $1.8M. Revenue declined 86.3% year over year. The balance sheet holds a net cash position of $10.8M. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Evogene Ltd reported revenue of $3.9M in FY2025 versus $930K in FY2021, a compound +42.7%/yr. Reported net income was −$8.5M in FY2025.
Is EVGN fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Evogene Ltd (EVGN) undervalued?
What is the fair value of EVGN?
What is the quality score of EVGN?
What is the revenue of Evogene Ltd (EVGN)?
What is the net profit margin of EVGN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.